Imatinib

Generic Name
Imatinib
Brand Names
Gleevec, Glivec, Imatinib Teva, Imatinib Accord
Drug Type
Small Molecule
Chemical Formula
C29H31N7O
CAS Number
152459-95-5
Unique Ingredient Identifier
BKJ8M8G5HI
Background

Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and ...

Indication

Imatinib is indicated for the treatment of adult and pediatric chronic myeloid leukemia with Philadelphia chromosome mutation (Ph+) in blast crisis, accelerated phase, or chronic phase after IFN-alpha therapy failure.Additionally, imatinib is also indicated to treat adult and pediatric Ph+ acute lymphoblastic leukemia, adult myelodysplastic/myeloproliferativ...

Associated Conditions
Accelerated Phase Chronic Myelogenous Leukemia (CML), Aggressive Systemic Mastocytosis, Chordomas, Chronic Eosinophilic Leukemia, FIP1L1-PDGFRα fusion kinase status unknown Chronic eosinophilic leukemia, FIP1L1-PDGFRα fusion kinase status unknown Hypereosinophilic syndrome, Gastrointestinal Stromal Tumor (GIST), Hypereosinophilic Syndrome (HES), Metastatic Gastrointestinal Stromal Tumor (GIST), Metastatic Melanoma, Myelodysplastic Syndrome, Myeloproliferative Disorders (MPD), Refractory Acute Lymphoblastic Leukemia (ALL), Blast phase Chronic myeloid leukemia, CKit mutational status unknown Aggressive systemic mastocytosis, Metastatic Dermatofibrosarcoma protuberans, Newly diagnosed Acute Lymphoblastic Leukaemia, Newly diagnosed, chronic phase Chronic myeloid leukemia, Recurrent Dermatofibrosarcoma protuberans, Refractory, chronic phase Chronic myeloid leukemia, Unresectable Gastrointestinal stromal tumor
Associated Therapies
-
Clinical Trials
Related News
onclive.com
·

Tailored Approaches to TKI Dosing Allow for Treatment-Free Remissions and Reduced ...

Patients with CML benefit from timely initiation, appropriate dosing, and potential treatment discontinuation with TKIs like bosutinib, which showed 81.1% achieving or sustaining CCyR in the BYOND trial. Ongoing research aims to identify novel agents offering deeper, longer-lasting responses without compromising safety or increasing costs. Bosutinib's safety profile, particularly its low cardiovascular AEs, differentiates it from other TKIs, making it a preferred option for long-term use.

Related Clinical Trials:

Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors
koreabiomed.com
·

Experts call for reform to integrate innovative medical technologies in Korea

Korea faces hurdles integrating innovative medical tech due to regulatory and reimbursement issues, as discussed at the K-Healthcare Business Forum. Medical IP's AI-based imaging solutions, like DeepCatch X, aim to replace traditional tests but face adoption challenges. Guardant Health urges regulatory reform for liquid biopsy access, while Ybrain's neuroengineering innovations struggle with market entry and reimbursement.
cancer.gov
·

Trial Supports Uninterrupted Use of Imatinib for GIST

New clinical trial results suggest that people with advanced gastrointestinal stromal tumors (GIST) should continue imatinib therapy without interruption, as discontinuation leads to more rapid disease progression and shorter survival. The trial, conducted over up to 20 years, found that those who stopped imatinib experienced faster resistance and poorer outcomes compared to those who continued treatment.
kgw.com
·

How a Portland doctor's discovery is inspiring the future of cancer research

Dr. Brian Druker developed Gleevec, a drug that targets specific leukemia cells, extending patients' lives. He now leads OHSU's Knight Cancer Institute, focusing on precision medicine and early cancer detection through blood tests.
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy